MNTA: Unless they sign another collaboration agreement for it upon FDA filing!
Regarding M178/249: I understand that both generic Lovenox and generic Copaxone are Worldwide agreements and might be filed by Sandoz in the EU at some point. However, it is unclear to me if this is the case for FoB's M178/249.
If so, Sandoz needn't wait for the US Congress to pass FoB legislation for EU filings once the molecules are "ready;" moreover, sales of the 2 drugs I mused about are almost equal in both territories... and certainly will garner sales in excess of $2B each for 2009 in the EU alone.
Given the multitude of other complex compounds out there, it isn't unreasonable to expect more collaborations from Sandoz or others, depending on MNTA's ability to scale up research. This is particularly true given the USPTO's stance on patents of late regarding number of claims per submission, etc.
Q: Is the M178/249 collaboration Worldwide?
Q: If M118 shows promise in PII, will they partner it and with whom?
Market Data 
Markets 
AI
